(Q34450697)

2 August 2017

Clinical and biological effects of mifepristone treatment for psychotic depression (English)

1 reference

2 August 2017

1 reference

1 reference

Benjamin H Flores

1

1 reference

2 August 2017

Heather Kenna

2

1 reference

2 August 2017

Jennifer Keller

3

1 reference

2 August 2017

Hugh Brent Solvason

4

1 reference

2 August 2017

Alan F Schatzberg

5

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

2 August 2017

Neuropsychopharmacology

1 reference

2 August 2017

31

1 reference

2 August 2017

628-636

1 reference

2 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300884

2 August 2017

0 references

cites work

Rapid reversal of psychotic depression using mifepristone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

The validity of major depression with psychotic features based on a community study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Mifepristone (RU486): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

DST studies in psychotic depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Decreased memory performance in healthy humans induced by stress-level cortisol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Prevalence of depressive episodes with psychotic features in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Corticosterone, brain mineralocorticoid receptors (MRs) and the activity of the hypothalamic-pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Challenges in the treatment of depression with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

A corticosteroid/dopamine hypothesis for psychotic depression and related states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

The pharmacological treatment of delusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Psychotic depression and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Mineralocorticoid receptor function in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Aging and cortisol resistance to suppression by dexamethasone: a positive correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

Functional biology of intestinal goblet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

The clinical and neuroendocrine features of psychotic depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

Disrupted 24-hour Patterns of Cortisol Secretion in Psychotic Depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300884

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300884

1 reference

Dimensions Publication ID

2 August 2017

1021099488

0 references

Fatcat ID

release_gfu5uuokyfgkbnljslopxu64e4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gfu5uuokyfgkbnljslopxu64e4

24 November 2022

mapped directly with Wikidata item

1 reference